jmjd-2 Antibody

What is JMJD2 and why is it important in epigenetic research?

JMJD2 (also known as KDM4) proteins are histone demethylases that play crucial roles in epigenetic regulation by removing methyl groups from specific histone residues. JMJD2B specifically demethylates H3K9me2, H3K27me2, and H3K23me2 and contains a PHD finger domain that interacts with H3K4me3 . These enzymes are critical for controlling chromatin structure and gene expression patterns.

The importance of JMJD2 proteins extends beyond basic epigenetic mechanisms to disease relevance. JMJD2B has been implicated in multiple cancer types, including prostate cancer where it functions as a transcriptional cofactor . In breast cancer, JMJD2B is regulated by both estrogen receptor alpha (ERα) and hypoxia-inducible factor 1-alpha (HIF-1α), driving cancer cell proliferation by epigenetically regulating cell cycle genes including CCND1, CCNA1, and WEE1 . The dual regulation of JMJD2B by both ERα and hypoxia pathways suggests it may represent a convergence point in breast cancer progression mechanisms.

How should JMJD2 antibodies be validated before experimental use?

Thorough validation of JMJD2 antibodies is essential for ensuring experimental reliability. A comprehensive validation strategy should include:

• Western blot analysis with proper controls: The literature demonstrates effective validation using western blot where a JMJD2-1.2 antibody detected a ~120 kDa band in wild-type lysates that was absent in mutant lysates (tm3713 and zr1010) . This confirms antibody specificity against the target protein.

• Testing in multiple applications: If planning to use the antibody for immunohistochemistry, immunofluorescence, or immunoprecipitation, validation should be performed specifically for each application. For immunohistochemistry, antigen retrieval conditions and antibody concentration should be optimized, as demonstrated in protocols using anti-JMJD2B polyclonal antibodies at 0.4 μg/mL concentration .

• Knockout/knockdown controls: The most stringent validation includes testing in genetic models where the target protein is absent or significantly reduced. This approach effectively eliminates false positives.

• Cross-reactivity assessment: Due to sequence homology among JMJD2 family members, antibodies should be tested against all family proteins to ensure specificity for the intended target.

• Peptide competition assays: Pre-incubation of the antibody with immunizing peptide should abolish specific signals in western blots or immunostaining.

What are the optimal methods for detecting JMJD2 enzymatic activity?

Researchers have multiple methodological options for detecting JMJD2 enzymatic activity, each with distinct advantages:

How can JMJD2 antibodies be used to study subcellular localization?

JMJD2 antibodies are valuable tools for examining the subcellular localization patterns of these important epigenetic regulators. Research indicates that:

• Immunofluorescence applications: JMJD2-1.2 localizes to the nucleoplasm throughout the entire germline, particularly in oocytes, as demonstrated through immunostaining of excised gonads . This suggests a dominant nuclear localization pattern consistent with its function as a histone-modifying enzyme.

• Nuclear versus cytoplasmic distribution: When performing immunohistochemistry with JMJD2B antibodies, researchers have found it informative to separately score the intensity of expression in both nuclear and cytoplasmic compartments of neoplastic cells . This approach acknowledges the potential for differential localization that may have functional significance.

• Methodological considerations: For optimal detection of JMJD2 proteins:

  • Proper fixation is critical (paraformaldehyde for immunofluorescence)

  • Antigen retrieval may be necessary (e.g., Tris-EDTA, pH 9.0 under pressure for IHC applications)

  • Controls should include cells known to express or lack the target protein

• Comparative analysis with interacting proteins: Co-localization studies with known JMJD2 interactors (such as transcription factors like JUN or ETV1 in prostate cancer cells) can provide insight into functional complexes .

What are the key differences between JMJD2 family members relevant to antibody selection?

The JMJD2 family comprises several members with both shared and distinct characteristics that influence antibody selection:

When selecting antibodies:

• Epitope considerations: Target unique regions to avoid cross-reactivity between family members.

• Application compatibility: Verify the antibody has been validated for your specific application (ChIP, western blot, immunofluorescence).

• Species reactivity: Ensure compatibility with your experimental model system.

• Post-translational modification sensitivity: Some antibodies may have reduced affinity when the target protein is post-translationally modified, which is relevant as JMJD2B can be methylated on multiple lysine residues .

How can JMJD2 antibodies be used to investigate post-translational modifications of JMJD2 proteins?

JMJD2 proteins themselves undergo post-translational modifications that regulate their function. Research has demonstrated that JMJD2B can be methylated on up to six different lysine residues by the SET7/9 methyltransferase . To investigate these modifications:

• Immunoprecipitation followed by western blotting: JMJD2B can be immunoprecipitated and then probed with methyl-lysine specific antibodies. Research has shown that a p53-K372me antibody can recognize methylated JMJD2B when it is coexpressed with SET7/9 . This approach requires:

  • High-affinity antibodies for the immunoprecipitation step

  • Modification-specific antibodies for detection

  • Appropriate controls (e.g., catalytically inactive SET7/9 H297A mutant)

• In vitro methylation assays with recombinant proteins: Researchers have divided JMJD2B into four fragments as GST fusion proteins to identify which regions could be methylated by SET7/9 in radioactive in vitro methylation experiments . This approach allows precise mapping of modification sites.

• Mutational analysis: After identifying potential modification sites, researchers can generate lysine-to-arginine mutations to assess functional consequences. Studies have shown that mutating methylation sites in JMJD2B to arginine residues led to diminished coactivation of the JUN transcription factor in prostate cancer models .

• Correlation studies in clinical samples: The expression of JMJD2B in human prostate tumors positively correlates with both SET7/9 and JUN levels, supporting functional relationships between these proteins .

What are the methodological considerations for using JMJD2 antibodies in chromatin immunoprecipitation (ChIP)?

ChIP experiments with JMJD2 antibodies require careful methodological planning:

• Crosslinking optimization: Standard formaldehyde crosslinking (1% for 10 minutes) may be suitable for most applications, but dual crosslinking with DSG (disuccinimidyl glutarate) followed by formaldehyde can improve capture of protein-protein interactions.

• Sonication parameters: Aim for chromatin fragments of 200-500 bp, optimizing sonication conditions based on cell type and equipment.

• Antibody selection criteria:

  • Choose antibodies raised against epitopes that remain accessible when the protein is bound to chromatin

  • For JMJD2B specifically, consider antibodies targeting regions outside the JmjC catalytic domain and PHD finger domain that may be engaged with histone substrates

  • Use antibodies validated specifically for ChIP applications

• Controls and normalization:

  • Include IgG negative controls

  • Input normalization is essential

  • Consider including ChIP for histone marks known to be JMJD2 substrates (H3K9me2/3, H3K27me2, H3K23me2) as functional controls

• Data analysis considerations:

  • For gene-specific analysis, design primers for regions where JMJD2 binding is expected based on known functions

  • For JMJD2B in cancer models, consider regions associated with cell cycle genes (CCND1, CCNA1, WEE1) that are known to be regulated by JMJD2B

  • For genome-wide studies, enrichment analysis of ERα target genes can be performed as described in breast cancer research

How can researchers overcome challenges in detecting JMJD2-protein interactions?

Detecting protein interactions involving JMJD2 family members presents several technical challenges:

• Specificity issues within the JMJD2 family:

  • Use highly specific antibodies validated against other family members

  • Consider epitope-tagged versions of JMJD2 proteins for cleaner interaction studies

  • Validate interactions through reciprocal co-immunoprecipitation experiments

• Context-dependent interactions:

  • JMJD2B interacts differentially with transcription factors depending on its methylation status

  • SET7/9-mediated methylation of JMJD2B affects its cooperation with JUN but not with ETV1 in prostate cancer models

  • Design experiments to capture condition-specific interactions (e.g., normoxia vs. hypoxia for HIF-1α interactions)

• Technical approach optimization:

  • Buffer conditions can significantly impact interaction detection (consider salt concentration, detergent type and concentration)

  • For weak or transient interactions, consider chemical crosslinking before lysis

  • Use cell-permeable crosslinkers for in vivo interaction stabilization

• Validation strategies:

  • Confirm interactions using multiple methodologies

  • Use truncation mutants to map interaction domains

  • Consider proximity-based methods (BioID, APEX) for detecting weak or transient interactions

How can JMJD2 antibodies be used to study the role of JMJD2 in cancer progression?

JMJD2 proteins, particularly JMJD2B, play significant roles in multiple cancer types. Research approaches using JMJD2 antibodies include:

• Expression analysis in clinical samples:

  • Immunohistochemistry with JMJD2B antibodies can assess expression patterns in cancer tissues

  • Separate scoring of nuclear and cytoplasmic expression provides greater insight

  • Combined analysis with other markers (e.g., JMJD2B with hypoxia marker CA9) can stratify patients into prognostic subgroups

• Mechanistic studies:

  • Investigate transcription factor interactions through co-immunoprecipitation

  • JMJD2B interacts with oncogenic factors like JUN in prostate cancer and is regulated by ERα and HIF-1α in breast cancer

  • Examine how post-translational modifications affect these interactions (e.g., SET7/9-mediated methylation impacts JMJD2B's cooperation with JUN)

• Functional pathway analysis:

  • Combined ChIP and gene expression analysis to identify direct targets

  • JMJD2B epigenetically regulates cell cycle genes (CCND1, CCNA1, WEE1) in breast cancer

  • Use gene expression profiling after JMJD2B manipulation as demonstrated in MCF7 cells

• Response to therapeutic interventions:

  • Monitor changes in JMJD2B levels, localization, and interactions following treatment

  • Assess changes in histone modification patterns at JMJD2B target genes

What methodology should be used to study JMJD2 in stress response pathways?

The involvement of JMJD2 proteins in cellular stress responses, including hypoxia and replication stress, can be investigated through multiple experimental approaches:

• Hypoxia response studies:

  • JMJD2B is regulated by HIF-1α in breast cancer models

  • Experimental design should include:

    • Controlled oxygen conditions (normoxia vs. hypoxia chambers)

    • Time-course analysis to capture dynamic responses

    • Combined immunoprecipitation and western blotting to detect changes in JMJD2B levels, modifications, and interactions

    • ChIP analysis to identify hypoxia-specific genomic targets

• Replication stress response:

  • JMJD2-1.2 appears to be involved in replication stress protection

  • Key methodological considerations include:

    • Treatment with replication stress inducers (e.g., hydroxyurea at 25-50 mM for 16 hours)

    • Assessment of embryonic lethality in model organisms as a phenotypic readout

    • Evaluation of DNA synthesis through markers like Cy3-dUTP incorporation

    • Examination of cell cycle progression through phosphorylated H3 (pH3) expression

• Integrated multiparameter analysis:

  • Combine assessment of:

    • JMJD2 subcellular localization (nuclear vs. cytoplasmic)

    • Enzymatic activity (using fluorometric assays)

    • Target histone modification status

    • Cell cycle and survival markers

This integrated approach allows researchers to connect JMJD2 function directly to cellular outcomes under various stress conditions, providing insight into potential therapeutic targeting strategies.